Evropska unija - danščina - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immune sera og immunoglobuliner, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

grünenthal gmbh - zolmitriptan - næsespray, opløsning - 5 mg/dosis

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

cheplapharm arzneimittel gmbh - quetiapin fumarat - depottabletter - 150 mg

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

cheplapharm arzneimittel gmbh - quetiapin fumarat - depottabletter - 200 mg

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

cheplapharm arzneimittel gmbh - quetiapin fumarat - depottabletter - 300 mg

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

cheplapharm arzneimittel gmbh - candesartancilexetil - tabletter - 16 mg

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

cheplapharm arzneimittel gmbh - candesartancilexetil - tabletter - 32 mg

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

cheplapharm arzneimittel gmbh - candesartancilexetil - tabletter - 8 mg

Evropska unija - danščina - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Danska - danščina - Lægemiddelstyrelsen (Danish Medicines Agency)

astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 2,25+80 mikrog/dosis